Great. Thank you, Karen, and good morning, everyone. DuPont executed well in the quarter and delivered strong results despite macroeconomic headwinds. We continued our momentum with particularly robust volume growth in agriculture, food and enzyme markets. Company sales were up 7% despite a 3% currency headwind. Excluding currency, sales were up in all regions. Sales to developing markets grew 11% versus a very strong comp. While volumes were down in Europe and Asia, we continue to see sequential improvement on a seasonally adjusted basis. Volumes were up 5% and 3% in China and India, respectively, versus the second quarter of 2011, which is another measure of good momentum in the regions. Underlying earnings grew 8% to $1.48 per share. On a segment level, pretax operating income was up 13% excluding Pharmaceuticals. I'd like to highlight some of the important milestones from the quarter. First, we passed the one-year anniversary of the Danisco acquisition in May. The contributions and benefits from the acquisition have exceeded our expectation. We added 2 very attractive businesses to our portfolio and identified significant opportunities for cost and revenue synergies. This newly created reporting segments of Nutrition & Health and Industrial Biosciences delivered strong performance this quarter and are expected to combine for over $4.5 billion in sales this year with a pretax operating margin in the 10% to 14% range. We will deliver $130 million of cost synergies by year end and expect additional productivity and margin expansion in 2013 and beyond. Another important milestone in the quarter was the conclusion of the northern hemisphere planting season. For the first half, Ag segment results were up 15% and pretax operating income up 16% driven by new products, strong relationships with our growers and an ever-expanding global footprint. In addition to a strong foundation in North America, we have built solid businesses in Eastern Europe, Latin America and China, which offer additional attractive growth. Earlier this quarter, we announced government approval of the acquisition of Pannar Seed company, a leader in Africa, as yet another example of our global build-out. Finally, I would be remiss if I didn't highlight innovation milestones. We're tracking well versus our target of having 30% sales from new products introduced within the last 4 years. I'd like to give just one new product example from the quarter. Our performance polymers business responded quickly to address the global shortage of PA-12, a critical polymer for automotive applications. We accelerated the introduction of new grades of our Zytel product to allow the automotive industry to continue to produce parts with alternative materials. The contribution to business results is small in the quarter, but importantly, we demonstrated, again, DuPont to be a valued partner in helping the auto industry respond to a critical shortage. Now I'll turn the call over to Nick and Karen to review the quarter in more detail. Then I'll come back and close out the call with our views on the outlook; so, Nick.